---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-207601"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:37:57.012084+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003

## Summary
- 100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.
- Favorable safety: no Grade >3 CRS or ICANS observed; 44 patients dosed across three studies to date.
- Median progression-free survival of 23.1 months in rrMM patients, including those with extramedullary disease.
- All 10 evaluable REDEEM-1 patients achieved CR per IMWG criteria; one prior BCMA CAR-T patient did not respond.
- Company plans to meet with FDA later this year to discuss initiating a U.S. registrational study.

## SEC filing metadata
- accession: 0001193125-26-207601
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526207601/0001193125-26-207601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526207601/d93617d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-207601
- JSON: https://secwatch.observer/filing/0001193125-26-207601.json
- Plain text: https://secwatch.observer/filing/0001193125-26-207601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.